医药行业BD交易井喷，2025全年首付款大涨226%，交易模式从“单次授权”迈向“共同开发”

Core Insights - The surge in the stock price of 3SBio and its subsidiary Sanofi's recent A-share market performance is driven by a significant $60.5 billion licensing deal with Pfizer for the anti-cancer drug SSGJ-707, marking a record for upfront payments in domestic BD transactions [1] - The year 2025 has seen a remarkable increase in business development (BD) activities in the pharmaceutical sector, with total transaction values exceeding $130 billion, including over $7 billion in upfront payments [1][2] - The evolution of BD transaction models reflects changing industry dynamics, moving from simple licensing agreements to more complex co-development and risk-sharing arrangements [1][9] BD Transaction Trends - In 2025, 62% of BD transactions involved early-stage assets, with a notable increase in deals for molecules in clinical phases I and II, indicating a shift towards earlier-stage investments [3][4] - Major multinational corporations (MNCs) have significantly increased their collaborations with Chinese firms, with top companies like GSK and Pfizer participating in 35 deals, a tenfold increase from 2015 [3] - High-value transactions involving molecules in late-stage clinical trials are becoming more common, providing greater certainty and stability to the BD market [4] Asset Deal Dynamics - The trend towards asset deals rather than full company acquisitions allows pharmaceutical companies to acquire specific assets without the burden of integrating entire organizations [7][10] - The focus on high-demand therapeutic areas such as bispecific antibodies (bsAbs), antibody-drug conjugates (ADCs), and GLP-1 drugs has led to a concentration of BD activities in these segments [7][8] - The bispecific antibody sector alone accounted for nearly $3.5 billion in upfront payments, representing 49.8% of all BD upfront payments in 2025, with a year-on-year growth of 414.7% [8] Innovative Collaboration Models - New collaborative models such as platform-based deals and joint development agreements are emerging, allowing for deeper partnerships beyond traditional licensing [10][11] - The NewCo model, which involves creating new entities for specific pipeline rights, is gaining traction, although it currently represents a smaller share of the overall BD landscape [11][12] - The shift towards strategic alliances emphasizes shared risks and benefits, enhancing long-term collaboration between companies [11][12] Future Outlook - The BD landscape is expected to continue evolving, with a focus on the long-term value of research and development capabilities as companies navigate the complexities of global markets [12][14] - The successful execution of BD deals will depend on the ability of companies to translate these agreements into tangible innovations and market successes [14]